Imidazole: a selective inhibitor of thromboxane synthetase.

PubWeight™: 2.48‹?› | Rank: Top 2%

🔗 View Article (PMID 558637)

Published in Prostaglandins on April 01, 1977

Authors

S Moncada, S Bunting, K Mullane, P Thorogood, J R Vane, A Raz, P Needleman

Articles citing this

Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol (1981) 2.79

Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest (1980) 2.06

Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency. J Clin Invest (1980) 1.91

Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest (1979) 1.44

Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Actions (1981) 1.36

13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A (1979) 1.33

Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. J Clin Invest (1983) 1.33

U-46619, a selective thromboxane A2-like agonist? [proceedings]. Br J Pharmacol (1980) 1.28

Effects of modulators of arachidonic acid metabolism on the synthesis and release of slow-reacting substance of anaphylaxis. Br J Pharmacol (1979) 1.21

Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated saline-perfused rabbit lungs. J Clin Invest (1984) 1.20

Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10

Lymphocyte traffic through antigen-stimulated lymph nodes. II. Role of Prostaglandin E2 as a mediator of cell shutdown. Immunology (1981) 1.09

Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat. Br J Clin Pharmacol (1983) 0.93

Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol (1986) 0.90

Selective inhibition of thromboxane biosynthesis in human blood mononuclear cells and the effects of mitogen-stimulated lymphocyte proliferation. Br J Pharmacol (1981) 0.89

CGS 12970: a novel, long acting thromboxane synthetase inhibitor. Br J Pharmacol (1985) 0.87

Lactic acidosis, prostaglandin E1, and colchicine. Br Med J (1978) 0.86

Prostaglandins mediate the vasodilatory effect of mannitol in the hypoperfused rat kidney. J Clin Invest (1981) 0.85

The prostanoids in hemostasis and thrombosis: a review. Am J Pathol (1980) 0.83

Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol (1979) 0.81

Metabolism of arachidonic acid and its endoperoxide (PGH2) to myotropic products in guinea-pig and rabbit isolated lungs. Br J Pharmacol (1980) 0.81

Gram-positive bacteria-induced granulocytopenia and pulmonary leukostasis in rabbits. Infect Immun (1982) 0.80

Determination of specific inhibitors of thromboxane A2 formation. Br J Pharmacol (1980) 0.79

Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide. Br J Pharmacol (1980) 0.78

Effect of sodium removal on tension and membrane potential after inhibition of the sodium pump in dog Purkinje fibres. J Physiol (1978) 0.77

Hypersensitivity to methoxamine in atria isolated from streptozotocin-induced diabetic rats. Br J Pharmacol (1986) 0.77

Pharmacologic characterization of immune complex induced bronchoconstriction in guinea pigs. Agents Actions (1981) 0.75

1-n-Butylimidazole: a potent and selective inhibitor of 'thromboxane synthetase' [proceedings]. Br J Pharmacol (1978) 0.75

Biotransformation of arachidonic acid in the circulation of the dog [proceedings]. Br J Pharmacol (1978) 0.75

Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts. Br J Pharmacol (1981) 0.75

Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention. West J Med (1981) 0.75

Articles by these authors

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44

Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41

Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19

Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93

Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85

Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66

Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34

The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90

Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79

L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69

Prostaglandins released by the spleen. Nature (1968) 7.61

Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (1985) 6.86

Arachidonic acid metabolism. Annu Rev Biochem (1986) 6.56

Nitric oxide synthases in mammals. Biochem J (1994) 6.50

A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30

Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96

Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87

Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23

A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77

Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55

Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49

Inactivation of prostaglandins by the lungs. Nature (1970) 4.47

Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44

Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23

Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19

Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11

An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98

Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A (1993) 3.93

Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74

Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74

Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70

The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63

Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55

Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54

Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest (1968) 3.52

Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43

The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem (1990) 3.34

Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30

Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29

Influence of preoperative anxiety on hypotension after spinal anaesthesia in women undergoing Caesarean delivery. Br J Anaesth (2012) 3.29

Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28

Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28

The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25

Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20

Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15

Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14

Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11

Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10

An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07

Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem (1988) 3.06

A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95

Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93

Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84

Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83

Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82

Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79

A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant (2007) 2.74

Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73

Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72

Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70

Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68

Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest (1990) 2.66

Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65

The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63

Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63